Ndrepepa Gjin, Groha Philipp, Lahmann Anna L, Lohaus Raphaela, Cassese Salvatore, Schulz-Schüpke Stefanie, Kufner Sebastian, Mayer Katharina, Bernlochner Isabell, Byrne Robert A, Fusaro Massimiliano, Laugwitz Karl-Ludwig, Schunkert Heribert, Kastrati Adnan
Deutsches Herzzentrum München, Technische Universität, Munich, Germany.
1.Medizinische Klinik, Klinikum rechts der Isar, Technische Universität, Munich, Germany.
Catheter Cardiovasc Interv. 2016 Aug;88(2):184-90. doi: 10.1002/ccd.26272. Epub 2015 Nov 3.
We aimed to assess the association between arterial hypertension and bleeding in patients undergoing percutaneous coronary intervention (PCI).
The impact of arterial hypertension on bleeding risk of patients with coronary artery disease undergoing PCI is unknown.
This study included 14,180 patients who underwent PCI. Bleeding was defined using the Bleeding Academic Research Consortium (BARC) criteria. Arterial hypertension was defined as treatment with antihypertensive drugs or a systolic blood pressure >140 mm Hg and/or diastolic blood pressure value >90 mm Hg documented on at least 2 occasions. The primary outcome was bleeding rate within 30 days of PCI.
Overall, 11,066 patients (78.0%) had arterial hypertension. Bleeding events occurred in 1,232 patients with arterial hypertension and 278 patients without arterial hypertension (11.1% vs 8.9%; odds ratio [OR] = 1.28, 95% confidence interval [CI] 1.11-1.46, P < 0.001). Access-site bleeding occurred in 730 patients with arterial hypertension and 175 patients without arterial hypertension (6.6% vs 5.6%: OR = 1.19 [1.01-1.41], P = 0.049). Non-access-site bleeding occurred in 502 patients with and 103 patients without arterial hypertension (4.5% vs 3.3%; OR = 1.39 [1.12-1.72], P = 0.003). After adjustment, arterial hypertension was significantly associated with any bleeding (adjusted OR = 1.41 [1.19-1.67], P < 0.001), access-site bleeding (adjusted OR = 1.36 [1.10-1.68], P = 0.005) and non-access-site bleeding (adjusted OR = 1.42 [1.09-1.83], P = 0.008). A history of arterial hypertension increased the risk of non-access-site bleeding (P = 0.002), whereas systolic blood pressure at the time of PCI increased the risk of access site bleeding (P = 0.018).
Arterial hypertension is associated with increased risk of bleeding during PCI procedures. © 2015 Wiley Periodicals, Inc.
我们旨在评估经皮冠状动脉介入治疗(PCI)患者中动脉高血压与出血之间的关联。
动脉高血压对接受PCI的冠状动脉疾病患者出血风险的影响尚不清楚。
本研究纳入了14180例接受PCI的患者。出血采用出血学术研究联盟(BARC)标准进行定义。动脉高血压定义为使用抗高血压药物治疗或至少两次记录的收缩压>140 mmHg和/或舒张压>90 mmHg。主要结局是PCI术后30天内的出血率。
总体而言,11066例患者(78.0%)患有动脉高血压。1232例患有动脉高血压的患者和278例没有动脉高血压的患者发生了出血事件(11.1%对8.9%;比值比[OR]=1.28,95%置信区间[CI]1.11 - 1.46,P<0.001)。730例患有动脉高血压的患者和175例没有动脉高血压的患者发生了穿刺部位出血(6.6%对5.6%:OR = 1.19[1.01 - 1.41],P = 0.049)。502例患有动脉高血压的患者和103例没有动脉高血压的患者发生了非穿刺部位出血(4.5%对3.3%;OR = 1.39[1.12 - 1.72],P = 0.003)。调整后,动脉高血压与任何出血(调整后OR = 1.41[1.19 - 1.6